CD205-targeted antibody-drug conjugate

DRUG CLASS:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

PD-L1 underexpression	Solid Tumor	PD-L1 underexpression	Solid Tumor	pembrolizumab + OBT076 Sensitive: C3 – Early Trials pembrolizumab + OBT076 Sensitive : C3	pembrolizumab + OBT076 Sensitive: C3 – Early Trials pembrolizumab + OBT076 Sensitive : C3
LY75 expression	Solid Tumor	LY75 expression	Solid Tumor	OBT076 Sensitive: D – Preclinical OBT076 Sensitive : D	OBT076 Sensitive: D – Preclinical OBT076 Sensitive : D

Associations(2)